Zimmer Biomet (ZBH) reported $2.02 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 4.3%. EPS of $2.31 for the same period compares to $2.20 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.01 billion, representing a surprise of +0.53%. The company delivered an EPS surprise of +0.43%, with the consensus EPS estimate being $2.30.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.43%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.75 per share when it actually produced earnings of $1.74, delivering a surprise of -0.57%.Over the last four quarters, ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Media Investors Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results (WARSAW, IN) February 6, 2025 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31 ...

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ( ...

The upcoming report from Zimmer Biomet (ZBH) is expected to reveal quarterly earnings of $2.30 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $2.01 billion, representing an increase of 3.7% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this ti ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, the company’s earnings of $1.74 missed the Zacks Consensus Estimate by 0.57%. ZBH beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average earnings surprise being 1.76%.Q4 Estimates for ZBHThe Zacks Consensus Estimate for revenues is pegged at $2.01 bi ...

Zimmer Biomet’s (ZBH) strategic product launches amid stabilizing market trends bolster our confidence in this stock. Yet, factors like macroeconomic uncertainties put pressure on the bottom line. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving ZBH's Share PriceZimmer Biomet has been witnessing strong market share gains within reconstructive Knees and Hips in key geographies in recent times despite macroeconomic challenges. The third quarter of 2024 marked the 11th consecutive quarter in ...

WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals ...

Company Overview - Zimmer Biomet Holdings Inc (NYSE: ZBH) is a prominent player in the Health Care Equipment Industry [1] - The company is strategically expanding its product portfolio, which could potentially alter its revenue growth trajectory [1] - Zimmer Biomet remains liquid and is well-positioned to execute its strategic initiatives [1] Industry Context - The Health Care Equipment Industry is a dynamic sector with significant growth potential [1] - Companies in this industry are focusing on product portfolio expansion to drive revenue growth [1] Strategic Initiatives - Zimmer Biomet is actively working on expanding its product offerings, which is a key strategy to enhance its market position [1] - The company's liquidity position supports its ability to invest in strategic growth initiatives [1]

Core Viewpoint - Zimmer Biomet is experiencing growth driven by strategic product launches and market expansion, particularly in emerging markets, despite facing macroeconomic challenges and operational pressures [2][8][9]. Group 1: Revenue Growth and Market Expansion - Strong revenue growth in emerging markets, particularly in the Asia Pacific region, is a key driver for Zimmer Biomet [2]. - The company is on a diversification journey with its S.E.T. business, expecting mid-single-digit sales growth to continue into 2025 and 2026 [3]. - Zimmer Biomet's international business exceeded sales expectations in the third quarter, supported by strong demand in reconstructive knees, hips, and S.E.T. categories [18]. Group 2: Product Launches and Market Share - The company anticipates significant market share gains from upcoming product launches, including the Oxford Partial cementless Knee and Z1 HAMMR in Europe [10]. - Zimmer Biomet has been witnessing strong market share gains in reconstructive knees and hips across key geographies [18]. Group 3: Financial Performance and Challenges - In the third quarter of 2024, Zimmer Biomet's net sales were negatively impacted by foreign exchange rates, with an expected adverse impact of 75 basis points for the full year [15]. - The company faced a 3.9% increase in the cost of products sold and a 3.1% rise in selling, general, and administrative expenses, leading to a contraction in adjusted gross and operating margins [12]. - Staffing shortages, supply chain issues, and geopolitical complications are creating significant pressure on revenues and operating profit [17].